 |
| Research article summary (published 29 Nov 2002): |
|
Free Full Text! See links below |
Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study.
Full Abstract
We investigated the effect of nicotine on three behavioral markers of risk for schizophrenia:
sustained attention (using the Continuous Performance Task (CPT)), antisaccade performance, and smooth pursuit. Smooth pursuit was investigated in two conditions, one in which attention was enhanced (monitoring target changes) and one in which attention was not enhanced (no monitoring). Patients with schizophrenia (n = 15) and controls (n = 14) were given a 14-mg nicotine patch in a double-blind, placebo-controlled, crossover design and plasma nicotine concentrations were monitored. Nicotine concentrations were similar in both groups. A Group x Drug interaction (p <.02) on CPT hits indicated that nicotine improved sustained attention in patients but not in controls. Nicotine significantly decreased antisaccade errors (p <.01) in both groups. A Drug x Monitoring condition interaction (p <.01) on pursuit gain indicated that nicotine significantly increased pursuit gain in the no-monitoring condition in patients and controls equally, but did not improve pursuit in the monitoring condition. Thus, improvement in pursuit may have been mediated via an effect on attention rather than by an effect on oculomotor function per se. In patients, the magnitude of improvement in attention on nicotine was correlated with the improvement on eye movement tasks. Thus, nicotine improves performance on both attention and oculomotor markers of risk for schizophrenia, possibly via common mechanisms.
Learn Faster Today Improve your study skills
Author information
Author/s: Dépatie, Lana (L); O'Driscoll, Gillian A (GA); Holahan, Anne-Lise V (AL); Atkinson, Victoria (V); Thavundayil, Joseph X (JX); Kin, N Ng Ying (NN); Lal, Samarthji (S);
Affiliation: Department of Psychiatry, McGill University, Quebec, Canada.
Journal and publication information
Publication Type: Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (Neuropsychopharmacology), published in United States. (Language: eng)
Reference: 2002-Dec; vol 27 (issue 6) : pp 1056-70
Dates: Created 2002/12/04; Completed 2003/01/24; Revised 2006/11/15;
PMID: 12464463, status: MEDLINE (last retrieval date: 11/6/2008)
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article (including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
|
|
Related articles
This article has not been indexed for related articles as yet, however you can still use the live related article search links below.
See a large map of 100+ related articles.